ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

Europe Business

ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has received final approval from The Nasdaq Capital Market LLC (“Nasdaq”) to list its common shares (the “Common Shares”) on Nasdaq. The Company’s Common Shares will begin trading on Friday, July 8th, 2022, under the symbol “PMN”.


The Company’s Common Shares will continue to trade on the Toronto Stock Exchange (TSX) under the same symbol “PMN” (its current symbol). Concurrent with the listing of ProMIS’ Common Shares on Nasdaq, the Common Shares will cease to be quoted on the OTCQB.


Eugene Williams, Chairman and CEO of ProMIS, said, “The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly traded company.  Nasdaq is the premier global stock exchange for life science and biotechnology companies.  We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.  I would like to thank our shareholders for their support, as well as everyone whose hard work has resulted in making ProMIS a member of the Nasdaq exchange.  This transformative step will help facilitate the continued advancement of our pipeline of differentiated therapies targeting misfolded proteins in Alzheimer’s, ALS, and other diseases with significant unmet need.”


ProMIS Neurosciences Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.


Twitter and LinkedIn